A 20 year experience in the management of non-tubal ectopic pregnancies in a tertiary hospital - a retrospective review.

IF 3.6 2区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Theodora Hei Tung Lai, Jennifer Ka Yee Ko, Hung Yu Ernest Ng
{"title":"A 20 year experience in the management of non-tubal ectopic pregnancies in a tertiary hospital - a retrospective review.","authors":"Theodora Hei Tung Lai, Jennifer Ka Yee Ko, Hung Yu Ernest Ng","doi":"10.1186/s12978-024-01838-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Non-tubal ectopic pregnancies account for < 10% of all ectopic pregnancies. Due to its rarity and wide variation in clinical practice, there is no guideline or consensus for its management. We reported our 20-year experience in the management of non-tubal ectopic pregnancies in a tertiary hospital.</p><p><strong>Methods: </strong>This is a retrospective review of all women admitted for non-tubal ectopic pregnancies from January 2003 to December 2022 in a tertiary hospital. Women with non-tubal ectopic pregnancies diagnosed by ultrasound or operation were included for analysis.</p><p><strong>Results: </strong>Within the study period, 180 women were diagnosed to have non-tubal ectopic pregnancies at a mean gestation of 6.8 weeks. 16.7% (30/180) were conceived via assisted reproduction. Medical treatment was the first-line management option for 81 women, of which 75 (92.1%) women received intralesional methotrexate administered under transvaginal ultrasound guidance. The success rate of intralesional methotrexate ranges from 76.5% to 92.3%. Intralesional methotrexate was successful even in cases with a positive fetal pulsation or with high human chorionic gonadotrophin levels up to 252605U/L. Twenty seven women were managed expectantly and 40 underwent surgery. Nine (11.1%), two (6.1%), and one (2.3%) women required surgery due to massive or recurrent bleeding following medical, expectant, or surgical treatment. Hysterotomy and uterine artery embolization were necessary to control bleeding in one Caesarean scar and one cervical pregnancy.</p><p><strong>Conclusions: </strong>Intralesional methotrexate is more effective than systemic methotrexate and should be considered as first line medical treatment for non-tubal ectopic pregnancies. It has a high success rate in the management of unruptured non-tubal ectopic pregnancies even in the presence of fetal pulsations or high human chorionic gonadotrophin levels, but patients may require a prolonged period of monitoring. Close surveillance and readily available surgery were required due to the risk of heavy post-procedural intra-abdominal bleeding.</p>","PeriodicalId":20899,"journal":{"name":"Reproductive Health","volume":"21 1","pages":"95"},"PeriodicalIF":3.6000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11218395/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12978-024-01838-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Non-tubal ectopic pregnancies account for < 10% of all ectopic pregnancies. Due to its rarity and wide variation in clinical practice, there is no guideline or consensus for its management. We reported our 20-year experience in the management of non-tubal ectopic pregnancies in a tertiary hospital.

Methods: This is a retrospective review of all women admitted for non-tubal ectopic pregnancies from January 2003 to December 2022 in a tertiary hospital. Women with non-tubal ectopic pregnancies diagnosed by ultrasound or operation were included for analysis.

Results: Within the study period, 180 women were diagnosed to have non-tubal ectopic pregnancies at a mean gestation of 6.8 weeks. 16.7% (30/180) were conceived via assisted reproduction. Medical treatment was the first-line management option for 81 women, of which 75 (92.1%) women received intralesional methotrexate administered under transvaginal ultrasound guidance. The success rate of intralesional methotrexate ranges from 76.5% to 92.3%. Intralesional methotrexate was successful even in cases with a positive fetal pulsation or with high human chorionic gonadotrophin levels up to 252605U/L. Twenty seven women were managed expectantly and 40 underwent surgery. Nine (11.1%), two (6.1%), and one (2.3%) women required surgery due to massive or recurrent bleeding following medical, expectant, or surgical treatment. Hysterotomy and uterine artery embolization were necessary to control bleeding in one Caesarean scar and one cervical pregnancy.

Conclusions: Intralesional methotrexate is more effective than systemic methotrexate and should be considered as first line medical treatment for non-tubal ectopic pregnancies. It has a high success rate in the management of unruptured non-tubal ectopic pregnancies even in the presence of fetal pulsations or high human chorionic gonadotrophin levels, but patients may require a prolonged period of monitoring. Close surveillance and readily available surgery were required due to the risk of heavy post-procedural intra-abdominal bleeding.

一家三甲医院治疗非输卵管异位妊娠的 20 年经验 - 回顾性总结。
背景:非输卵管异位妊娠占异位妊娠的大多数:这是对一家三甲医院自 2003 年 1 月至 2022 年 12 月期间因非输卵管异位妊娠入院的所有女性进行的回顾性研究。分析对象包括经超声波或手术诊断为非输卵管异位妊娠的妇女:在研究期间,180 名妇女被诊断为非输卵管异位妊娠,平均妊娠期为 6.8 周。16.7%的患者(30/180)是通过辅助生殖技术受孕的。81名妇女选择了药物治疗作为一线治疗方案,其中75名(92.1%)妇女在经阴道超声引导下接受了鞘内注射甲氨蝶呤治疗。氨甲蝶呤内注射的成功率从 76.5% 到 92.3% 不等。即使在胎儿搏动阳性或人类绒毛膜促性腺激素水平高达 252605U/L 的情况下,局部注射甲氨蝶呤也能取得成功。27 名妇女接受了期待治疗,40 名妇女接受了手术治疗。9名(11.1%)、2名(6.1%)和1名(2.3%)妇女在接受药物、待产或手术治疗后因大量出血或反复出血而需要手术。一名剖腹产瘢痕妊娠和一名宫颈妊娠患者需要进行子宫切开术和子宫动脉栓塞术来控制出血:椎管内甲氨蝶呤比全身甲氨蝶呤更有效,应被视为治疗非输卵管异位妊娠的一线药物。即使在胎儿搏动或人类绒毛膜促性腺激素水平较高的情况下,治疗未破裂的非输卵管异位妊娠的成功率也很高,但患者可能需要长期监护。由于术后腹腔内大量出血的风险,需要严密监测并随时进行手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Reproductive Health
Reproductive Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
6.00
自引率
5.90%
发文量
220
审稿时长
>12 weeks
期刊介绍: Reproductive Health focuses on all aspects of human reproduction. The journal includes sections dedicated to adolescent health, female fertility and midwifery and all content is open access. Reproductive health is defined as a state of physical, mental, and social well-being in all matters relating to the reproductive system, at all stages of life. Good reproductive health implies that people are able to have a satisfying and safe sex life, the capability to reproduce and the freedom to decide if, when, and how often to do so. Men and women should be informed about and have access to safe, effective, affordable, and acceptable methods of family planning of their choice, and the right to appropriate health-care services that enable women to safely go through pregnancy and childbirth.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信